Apexian Pharmaceuticals
Apex Therapeutics, based in Indianapolis, US, develops and markets drugs for cancer and eye diseases.
Founded
2005Apex Therapeutics, based in Indianapolis, US, develops and markets drugs for cancer and eye diseases.
Apexian Pharmaceuticals, based in Indianapolis, US, was founded with the core mission to develop and commercialize safe and effective therapies for life-threatening diseases mediated by the APE1/Ref-1 protein. The company focuses on creating pharmaceuticals aimed at treating cancer and ocular diseases. Apexian's vision is to significantly improve patient outcomes through innovative drug development, leveraging their expertise in targeting the APE1/Ref-1 protein pathway.
Notable affiliated individuals include members of the Board of Directors, Leadership Team, and Scientific Advisory Board, who bring extensive experience in pharmaceutical development and commercialization. Apexian has achieved key milestones in its research and development pipeline, advancing several preclinical and clinical programs. The company's impact lies in its potential to offer new treatment options for patients suffering from severe diseases, thereby addressing significant unmet medical needs.
Companies similar to Apexian Pharmaceuticals include AsclepiX Therapeutics, Aprea Therapeutics, Ocuphire Pharma and Arisaph Pharmaceuticals.
Apexian Pharmaceuticals was founded in 2005.
Apexian Pharmaceuticals' headquarters is located in Indianapolis, IN, US.
Apexian Pharmaceuticals' most recent funding round was for $100k (USD) in August 2021.
As of Aug 31, 2021, Apexian Pharmaceuticals has disclosed funding of $6.9M (USD). Undisclosed round amounts are excluded.
Apexian Pharmaceuticals has 5 employees as of Feb 5, 2024.
Arisaph Pharmaceuticals
